CardiALLO cell therapy - BioCardiaAlternative Names: CardiALLO
Latest Information Update: 23 Oct 2015
At a glance
- Originator BioCardia
- Class Antineoplastics; Stem cell therapies
- Mechanism of Action Stem cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Heart failure
- Preclinical Myocardial infarction